Nothing is more tiring than a chronic illness: Sushmita Sen

Bollywood actor recalls struggle with Addison’s disease


Entertainment Desk May 18, 2020

Bollywood actor Sushmita Sen has revealed that she was diagnosed with Addison’s disease back in 2014 but fought it with sheer determination and Nunchaku workout sessions.

This is a martial arts weapon, traditionally used in Okinawan style, with two sticks connected by a short chain or rope, reported Hindustan Times.

Sen gave an elaborate description of the experience in a new video she posted on YouTube. “After I was diagnosed with an auto-immune condition called Addison’s disease in September 2014, it left me feeling like I had no fight left in me...A fatigued body filled with immense frustration and aggression,” she recalled.

“The dark circles under my eyes can’t even begin to explain the dark times I endured for four long years. To have steroids substitute cortisol and to live with its innumerable side effects took its toll. There is nothing more tiring than to live with a chronic illness.”

Eventually, the former Miss Universe realised enough was enough. “I had to find a way of strengthening my mind, allowing my body to follow suit. So, I meditated with Nunchaku.”

Praising the art form, Sen added, “Aggression out, fight back in and pain turning into an art form, I healed in time. My adrenal glands woke up; no more steroids, no withdrawals and no auto-immune condition as of 2019. Lesson: No one knows your body better than you so listen to it. There is a warrior in all of us; never give up!”

In the end, the Mein Hoon Naa starlet thanked her Nunchaku teacher for all his help. “Thank you to my teacher Nupur Shikhare for being my rock through this journey. I love you guys!”

Sen also posted a picture from one of her workout sessions on Instagram and wrote, “Had to bring the journey and the #nunchaku back for YouTube.”

COMMENTS

Replying to X

Comments are moderated and generally will be posted if they are on-topic and not abusive.

For more information, please see our Comments FAQ